• Corpus ID: 6664942

Opening the flood gates: interferon-alpha treatment for Sjögren's syndrome.

@article{Shiozawa2000OpeningTF,
  title={Opening the flood gates: interferon-alpha treatment for Sj{\"o}gren's syndrome.},
  author={Shunichi Shiozawa and Joseph M. Cummins and Philip C. Fox},
  journal={BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy},
  year={2000},
  volume={13 5},
  pages={
          305-11
        }
}
  • S. Shiozawa, J. Cummins, P. Fox
  • Published 2000
  • Medicine, Biology
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Interferon (IFN)-alpha is the main IFN produced in response to viral infection. Low levels of IFNalpha can be detected in nasal secretions after exposure to viruses in vivo. Radioimmunoassay has shown that endogenous IFNalpha is low in children, reaches a peak in young adults, and gradually declines with aging. Importantly, this endogenous IFNalpha is significantly decreased in patients with Sjögren's syndrome (SS). IFNalpha has been tested as a therapeutic agent in patients with SS… 
Safety, Tolerability, and Immunogenicity of Interferons
TLDR
Current reports suggest that certain polymorphisms in type I IFN signaling molecules are associated with IFN-induced neutropenia and thrombocytopenia in patients with chronic hepatitis C, which may well explain the wide spectrum of IFN associated toxicities.
Associations of cigarette smoking with disease phenotype and type I interferon expression in primary Sjögren’s syndrome
TLDR
Investigating if smoking affects disease activity and disease phenotype in primary Sjögren’s syndrome found smoking was not associated with disease phenotype although patients with a higher cumulative cigarette consumption had worse symptoms in some disease domains.
Cigarette smoke attenuates the production of cytokines by human plasmacytoid dendritic cells and enhances the release of IL-8 in response to TLR-9 stimulation
TLDR
The data indicate that CSE has both the potential to diminish anti-viral immunity by downregulating the release of IFN-α and other pro-inflammatory cytokines while, at the same time, augmenting the pathogenesis of COPD via an IL-8 induced recruitment of neutrophils.
Cytotoxics or biologicals in the treatment of Sjögren’s syndrome?
TLDR
Biological agents against novel therapeutic targets including B-cell activating factor and costimulatory molecules are currently tested in ongoing trials.
Aquaporins in salivary glands and pancreas.
  • C. Delporte
  • Medicine, Biology
    Biochimica et biophysica acta
  • 2014